Alternating non-cross-resistant multiagent chemotherapy (ANCRC) and high-dose chemotherapy followed by autologous stem cell support (HDC-ASCS) in first remission to improve outcome in patients with T-cell lymphoma.
Potjana Jitawatanarat
No relevant relationships to disclose
Richa Dawar
No relevant relationships to disclose
Kaweesak Chittawatanarat
No relevant relationships to disclose
Nicolas Batty
No relevant relationships to disclose
Myron Stefan Czuczman
No relevant relationships to disclose
Francisco J. Hernandez-Ilizaliturri
No relevant relationships to disclose